Mirum Pharmaceuticals’ (MIRM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $66.00 price target on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.35 EPS, Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $1.00 EPS, FY2026 earnings at $5.48 EPS, FY2027 earnings at $6.98 EPS and FY2028 earnings at $10.38 EPS.

A number of other equities analysts have also recently weighed in on MIRM. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday. Evercore ISI raised their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Cantor Fitzgerald boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Stock Down 3.8 %

MIRM opened at $44.50 on Wednesday. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $48.89. The firm has a 50 day moving average price of $40.12 and a 200 day moving average price of $36.07. The company has a market cap of $2.14 billion, a PE ratio of -22.03 and a beta of 1.16. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.09 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period last year, the company posted ($0.57) earnings per share. The firm’s revenue was up 89.4% compared to the same quarter last year. Sell-side analysts expect that Mirum Pharmaceuticals will post -1.81 earnings per share for the current year.

Insider Activity

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the transaction, the senior vice president now owns 2,426 shares of the company’s stock, valued at $114,264.60. The trade was a 50.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC lifted its holdings in Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the last quarter. ProShare Advisors LLC acquired a new position in Mirum Pharmaceuticals during the 2nd quarter valued at approximately $213,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the 3rd quarter worth $215,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.